VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-09 pm EST			5-day change	1st Jan Change
0.5575 ^USD	-0.38%		-1.52%	-3.90%

Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

Transcript : VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

Published on 12/17/2025 at 12:21 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the VYNE Therapeutics conference call to discuss the merger of VYNE and Yarrow Bioscience. This call is being recorded for

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about VYNE Therapeutics Inc.

Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call
Dec. 17	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.	CI
Dec. 17	Vyne Therapeutics and Yarrow Bioscience announce merger agreement	RE
Nov. 06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
Nov. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	VYNE Therapeutics Inc. Announces Resignation of Christine Borowski as Member of the Board and as A Member of the Nominating and Corporate Governance Committee	CI
25-08-14	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
25-07-30	Sector Update: Health Care Stocks Decline in Late Afternoon Trading	MT
25-07-30	Sector Update: Health Care	MT
25-07-30	Top Midday Decliners	MT
25-07-30	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	CI
25-07-30	Vyne Therapeutics' Phase 2b Trial of Repibresib Gel in Nonsegmental Vitiligo Misses Primary Endpoint	MT
25-07-30	Vyne Therapeutics announces topline results from phase 2b trial with repibresib gel in nonsegmental vitiligo	RE
25-07-02	VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202	CI
25-05-08	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-25	VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell	MT
25-04-25	VYNE Therapeutics Provides Update on VYN202 Program	CI
25-04-08	Artiva Biotherapeutics Names New Chief Medical Officer	MT
25-03-17	Mindmed Appoints Matt Wiley as Chief Commercial Officer	CI
25-03-06	VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-02-19	Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis	RE
25-02-19	VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis	CI
25-01-06	VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	CI